Company intelligence / Profile preview

TheraCryf

Ownership: Private
Development stage: Other

Overview

TheraCryf is developing sulforaphane-based therapeutics for cancer, inflammation, and behavioral brain disorders. Its lead candidate Ox‑1 targets the orexin‑1 receptor for substance use disorders and anxiety and is at late pre-clinical stage. The company has licensed its lead asset SFX‑01 for neurodevelopmental indications to Stalicla, which will fund clinical development in autism spectrum disorder. TheraCryf retains rights to other indications.

Therapeutic areas: OncologyImmunologyPsychiatryNeurology
Modalities: Small moleculeSulforaphane-based drugs
Industry: Biotech

Drug pipeline

4 assets

sulforaphane

3 more assets in the full pipeline.

Request access →

Partnerships

Stalicla (licensed global rights for SFX‐01 in neurodevelopmental and schizophrenia indications; collaboration on ASD clinical program with Stalicla funding all activities)

Beyond the preview

Go deeper on TheraCryf.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraCryf.

Explore the full profile